Skip to content
OpenCapital
Get started

Neuropace, Inc. NPCE Q1 2026 earnings

Reported May 12, 2026 · After market close

Revenue$22.0MBeat by $355.4KDiluted EPS-$0.13Beat by $0.06
Revenue estimate$21.6M
EPS estimate-$0.19

Next report

Aug 11, 2026 (in a month)
Revenue estimate$22.6M
EPS estimate-$0.19

Financials

Q1 2026

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$578.57M+10.6%
Enterprise value$633.4M+11.5%
P/S5.8×-0.4×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Versus estimates

Revenue

Q1 2026$22.0MBeat by $355.4K
Q4 2025$26.6MBeat by $1.8MQ3 2025$27.4MBeat by $2.3MQ2 2025$23.5MMiss by $913.1KQ1 2025$22.5MMiss by $186.3KQ4 2024$21.5MMiss by $93.9K

Diluted EPS

Q1 2026-$0.13Beat by $0.06
Q4 2025-$0.08Beat by $0.06Q3 2025-$0.11Beat by $0.09Q2 2025-$0.26Miss by $0.02Q1 2025-$0.21Beat by $0.05Q4 2024-$0.18Beat by $0.07

Ask the moment Neuropace, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Neuropace, Inc. report Q1 2026 earnings?
Neuropace, Inc. (NPCE) reported Q1 2026 earnings on May 12, 2026 after market close.
What were Neuropace, Inc.'s Q1 2026 revenue and EPS?
Neuropace, Inc. reported revenue of $22.0M and diluted EPS of $-0.13 for Q1 2026.
Did Neuropace, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $21.6M by $355.4K. EPS beat the consensus estimate of $-0.19 by $0.06.
How did Neuropace, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 2.3% from $22.5M a year earlier and diluted EPS grew 38.1% from $-0.21.
Where can I find Neuropace, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001528287-26-000019) and the 10-Q periodic report (0001528287-26-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.